/ /

CLINICAL

Will new autoimmune drugs address cost concerns?Find out what’s in the drug pipeline for autoimmune disease.
The digital skin health revolutionMobile app for acne opens the door for use with skin aging and other aesthetic skin conditions.
Dermatology’s 2017 Game ChangersSeveral dermatologists go over what they're most excited about to see in 2017 in a number of different topics ranging from AD treatment to off-label technology use, to more male patients.
First-ever U.S. psoriasis treatment goalsThe National Psoriasis Foundation has recently published psoriasis treatment goals, which will help physicians and patients discuss treatment options and set expectations for outcomes.
December Clinical Considerations for NPs, PAsIn this month's Clinical Considerations, we take a look at AD and bullying, whether or not derms are doing enough for psoriasis patients, and the potential of Epicutaneous immunotherapy.
Novel immunomodulators expected to usher in new therapeutic eraA number of systemic and topical treatments for atopic dermatitis are being developed that feature novel mechanisms of action targeting the inflammatory axes involved in the disease.
Top 5 of 2016: Pediatric dermatologyThis year has seen many advancements in pediatric dermatologic care spanning inflammatory conditions to skin cancer as well as the nuances of these conditions in skin of color patients. These are the top 5 pediatric articles of 2016 from Dermatology Times.
Pearls to optimize safety, success with biologicsOne dermatologist describes his considerations for choosing a biologic to treat a patient with moderate-to-severe psoriasis, baseline assessments, and follow-up approach.
Study offers new insight into pediatric eczemaResearchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.
Advances in pediatric inflammatory skin diseaseExciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.

Poll

View Results